PARP Inhibitors in Advanced Prostate Cancer Care

PARP Inhibitors in Advanced Prostate Cancer Care Podcast CME Available: https://auau.auanet.org/node/37321 Host: Jay D. Raman, MD, FACS Guests: Maha Hussain, MD and Ganesh Raj, MD, PhD LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Identify approved PARP Inhibitors for prostate cancer and patients who may benefit from PARP Inhibitor‐based therapy. 2. Evaluate available clinical safety and efficacy data for PARP Inhibitors. 3. Describe indications and contraindications for PARP Inhibitors in patients with advanced prostate cancer. 4. Identify how to manage adverse events that patients may experience while taking a PARP Inhibitors. ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc. Sanofi Genzyme